Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.
A retrospective comparison was carried out on adult patients receiving HLA-identical allogeneic haemopoietic stem cell transplants from siblings in Australia in 1996, comparing bone marrow with G-CSF-mobilised peripheral blood stem cells. A total of 131 transplant recipients from nine centres were included in this study, of whom 79 received bone marrow, 44 blood stem cells and eight both. All but three of the 131 patients had cyclosporin and methotrexate as graft-versus-host disease prophylaxis. The minimum follow-up time for surviving patients is 27 months. Comparisons were carried out between the BM and PBSC groups. There were no significant differences between groups in age, sex, diagnosis, donor characteristics or pretransplant conditioning. Median time to neutrophil recovery of 0.5 x 10(9)/l was 14 days for PBSC recipients, compared to 19 days for marrow recipients (P < 0.0005). median time to platelet recovery of 20 x 10(9)/l was 17 days for PBSC recipients, compared to 28 days for marrow recipients (P < 0.0005). there were no significantly increased risks of either acute or chronic GVHD in the PBSC recipients. there were no significant differences between the groups in the incidence of major transplant-related complications, disease-free survival or overall survival.
Nivison-Smith
I
I
St Vincent's Hospital, Sydney, NSW, Australia.
Bradstock
K F
KF
Szer
J
J
Durrant
S
S
Dodds
A
A
Hermann
R
R
Schwarer
A P
AP
Gibson
J
J
To
L B
LB
Arthur
C
C
D000293:Adolescent; D000328:Adult; D001315:Australia; D001773:Blood Cells / Q000166:cytology / Q000637:transplantation; D001854:Bone Marrow Cells / Q000166:cytology; D016026:Bone Marrow Transplantation; D002423:Cause of Death; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000592:standards*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000379:methods / Q000592:standards; D014185:Transplantation, Isogeneic / Q000009:adverse effects / Q000379:methods / Q000592:standards; D016896:Treatment Outcome
D016179:Granulocyte Colony-Stimulating Factor